Our pipeline 2020

Microbiome Focused Product

We are currently exploring and optimizing single bacterial strains to deliver best-in-class microbiome-based biotherapies in obesity as well as metabolic disorders, inflammatory diseases and mood disorders.

Our single strain biotherapies are dedicated to unlocking the therapeutic value of Christensenella, as well as other keystone microbiome bacteria.


Yso1 is a development program aiming at harnessing the potential of Christensenella minuta as a novel therapy to treating obesity and metabolic disorders. 

This program is built on first-in-class scientific publications that have identified christensenella as a cornerstone of healthy human intestinal microbiota. The bacterial strain specifically selected for this program comes from YSOPIA Bioscience proprietary library. 
Yso1 showed strong preclinical efficacy results in preclinical animal models.

By finalizing the industrialization process for the manufacture of clinical batch of its Xla1 product candidate, YSOPIA Bioscience accomplished a key challenge in the production of anaerobic gut bacteria. 
Read cGMP manufacturing press release

YSOPIA Bioscience received FDA Investigational New Drug Approval to assess the safety and tolerability of Xla1 in adults with obesity and metabolic abnormalities in a Phase 1 clinical trial.Read IND approval press release

Yso2 & Yso3

Yso2 & Yso3 are development programs leveraging the potential of beneficial bacteria such as Christensenella by developing single strain biotherapies to treat patients suffering from inflammatory diseases

Many inflammatory disorders have been associated with alterations of the gut microbiome. YSOPIA Bioscience therefore focusses on restoring the gut microbial symbiosis specifically altered in some inflammatory pathologies using carefully selected single strain bacteria.

Our approach is supported by compelling epidemiological and clinical data that have demonstrated a strong link between the presence of keystone bacteria and reduced risks of developing inflammatory bowel disorders.

Our programs aim at selecting single strain bacteria with a significant anti-inflammatory activity for multiple indications. We expect that at least one clinical candidate will complete IND filing by end of 2021.

We are closely collaborating with Pr. Philippe Langella and his team, from the Micalis Institute (joint research unit between INRA, AgroParisTech and Paris-Saclay University), a cutting-edge European microbiology research organization.
Read our press release

more +

General review of gut microbiome changes in IBD showing consistant association between CD and a loss of Christensenellacea
Pittayanon, R., Lau, J.T., Leontiadis, G.I., Tse, F., Yuan, Y., Surette, M., and Moayyedi, P. (2019). Differences in Gut Microbiota in Patients With vs Without Inflammatory Bowel Diseases: a Systematic Review. Gastroenterology 1–52.

Important paper showing that loss of Christensenella is predictive of CD flare.
Braun, T., Di Segni, A., BenShoshan, M., Neuman, S., Levhar, N., Bubis, M., Picard, O., Sosnovski, K., Efroni, G., Farage Barhom, S., et al. (2019). Individualized Dynamics in the Gut Microbiota Precede Crohnʼs Disease Flares. Am. J. Gastroenterol. 1–10.


Yso4 is an exploratory program targeting the gut-brain axis for the treatment of mood disorders.

Over the last 5 years, there has been increasing evidence that the gut microbiome was associated with neurological and behavioral disorders, which led to the so called “gut-brain axis” concept.

Multiple complex mechanisms of action are at play in this relationship, and although a lot still to discover, there is strong support for an action of the gut microbiome on neurotransmitter and neuroinflammation.

YSOPIA Bioscience is therefore initiating research in this exciting area to harness the potential of carefully selected bacteria strains of Christensenellaceae to treat mood disorders, such as depression or anxiety.

In April 2020, YSOPIA Bioscience entered into an exclusive license agreement with Spanish National Research Council (CSIC), for its patent application dedicated to the therapeutic use of Christensenella gut bacteria in mood disorders
Read our press release

more +

Pr. John Cryan, a neuropharmacologist and microbiome expert from the University College Cork, shares surprising facts and insights about how our thoughts and emotions are connected to our gut.

Discover John Cryan on TEDMED

Microbiome & us
Nov 17, 2020
YSOPIA Bioscience secures €1.55M in non-dilutive funding from Bpifrance and the European Regional Development Fund |...
> more
Oct 13, 2020
We are looking for a R&D Microbiologist | WHAT WE OFFER An exciting opportunity to dive in your career with a...
> more
Press / Media
Nov 12, 2019
Biotechs investments disrupt Big Pharma business model The pharmaceutical industry is in a state of flux, with...
> more
Sep 6, 2019
Chaque semaine, Maddyness dresse le bilan des levées de fonds de la semaine qui vient de s’écouler. Cette semaine,...
> more
Apr 22, 2020
Keystone gut bacteria are the foundation of the whole microbial ecosystem because they provide very specific metabolic...
> more
Dec 6, 2019
The term “microbiome” refers to the collection of microorganisms (or microbiota) – including bacteria, viruses and...
> more
now on twitter
YSOPIA Bioscience

.@harvardmed researchers have, for the first time, described in mice how bacteria residing in the gut can protect f… t.co/MLKe5CZNYC

YSOPIA Bioscience © 2020 - all rights reserved terms and conditions